103 results about "Muscle loss" patented technology

The compositions comprise at least two ingredients selected from the group consisting of fish oil, L-arginine, vitamin E, vitamin C, vitamin B3, vitamin B5, vitamin B6, vitamin B1, vitamin B2, folic acid, biotin, vitamin B12, and are formulated for the prevention and / or treatment of a disease or condition associated with muscle decline in a subject in need thereof. Preferably, the subject in need is an individual at risk of or having renal failure, renal dysfunction or / and nephropathy, such as chronic nephropathy, protein energy consumption, end-stage nephropathy, renal failure due to hospitalization in an intensive care unit, acute kidney injury, and the muscle decline is selected from the group consisting of muscle depletion, muscle loss due to renal failure or dysfunction, muscle decline associated with chronic kidney disease, muscle loss due to hospitalization in intensive care units during renal failure, metabolic acidosis during chronic kidney disease, protein energy depletion, or a combination thereof. The method enables the prevention and / or treatment of at least one outcome of a disease or condition associated with muscle decline in a subject at risk of or having renal failure, renal dysfunction or / and kidney disease. The composition and the method can be used to improve the level of at least one amino acid.

The invention discloses a liver cancer post-transplantation muscle loss prediction method and device, and belongs to the technical field of biomedicine, and the method comprises the steps: constructing an unbalanced random forest model comprising a plurality of decision trees, independently predicting through the plurality of decision trees to obtain a plurality of high-risk or low-risk dichotomy prediction results, taking the proportion of the decision tree with the prediction result being high risk in all decision trees as the prediction probability of muscle loss after liver cancer liver transplantation finally output by the model; performing risk classification according to the prediction probability, and judging the postoperative muscle loss level of the patient as high risk, medium risk or low risk; constructing a decision tree model to layer prognosis of patients, and dividing the patients into a high-risk group, a medium-risk group and a low-risk group; and carrying out survival rate prediction in combination with liver transplantation standards and prognosis layering results of patients. According to the method, the muscle loss level after the liver transplantation can be accurately predicted, and a clinician can make a personalized treatment scheme and perform scientific management after the transplantation.

Disclosed herein are the Lactobacillus paracasei NB23 strain and a method of using the same to increase muscle mass and to prevent / treat metabolic syndrome. Administering an effective amount of the Lactobacillus paracasei NB23 strain or a metabolite thereof to an individual can effectively produce the effect of treating or preventing diseases associated with muscle loss or insufficient muscle mass, metabolic syndrome, and diseases related thereto.

The invention provides a soybean peptide with an effect of preventing and / or treating chronic nephritis as well as a preparation method and application of the soybean peptide, and belongs to the technical field of bioactive peptides. According to the preparation method of the soybean peptide mixture provided by the invention, a three-step enzymolysis mode is adopted, the molecular weight of soybean peptide is controlled to be 1000 Daltons or below, micromolecular oligopeptide is used as a main component, and the prepared soybean peptide mixture is low in sodium, phosphorus and potassium content and capable of improving the nutritional status and muscle loss condition of nephritis patients. The prepared soybean peptide mixture is further separated and purified, the purified soybean peptide mixture, the single-chain polypeptide S1 and the single-chain polypeptide S2 are obtained, the content of uric acid and creatinine can be effectively reduced, inflammation can be inhibited, and the soybean peptide is expected to be developed into a novel polypeptide medicine for preventing and / or treating chronic kidney diseases.

The present invention provides an extract having excellent anti-obesity and muscle cell loss prevention effects, and a single compound obtained therefrom. A pharmaceutical composition for preventing and treating muscle loss and anti-obesity, comprising an extract of Rhododendron mucronulatum as an active ingredient, is provided.

The invention relates to application of a yeast peptide-derived polypeptide in promoting proliferation and differentiation of myoblasts and a composition, and belongs to the technical field of biological medicines and nutrition and health care. The amino acid sequence of the polypeptide comprises SEQ ID No.1 (LGGPLL), SEQ ID No.2 (PQAVTI), SEQ ID No.3 (VASGGL) or SEQ ID No.4 (LGPTGISM, and the polypeptide can be used for remarkably promoting the proliferation and the cell cycle progress of C2C12 myoblasts and up-regulating the expression level of myogenic protein. The polypeptide can be used as an active component to be applied to development of anti-sarcopenia related medicines or functional food compositions. Cell experiments prove that the polypeptide has a good muscle promoting function and is suitable for intervention of senile muscle loss such as sarcopenia and the like.

The present disclosure relates to a composition for preventing or treating muscle disease, comprising CXCL14 as an active ingredient. According to the present disclosure, it was confirmed that CXCL14 increased muscle differentiation and synthesis, thereby increasing muscle mass. In addition, it was confirmed that in LPS-induced muscular atrophy or DEX-induced muscular dystrophy, CXCL14 inhibited muscle loss, increased the expression of muscle synthesis and differentiation factors, and inhibited the expression of muscle degradation proteins. In addition, it was confirmed that CXCL14 promoted muscle synthesis and differentiation and inhibited the muscle degradation even in vivo.

Methods for treating muscle loss and exercise capacity pathologies by controlling osteocalcin release, and compositions therefor, are provided.

The application discloses application of O-acyl-alpha-hydroxy acid compounds in weight loss and lipid reduction, and belongs to the fields of biological medicine manufacturing, biological medicine use and functional food development. The O-acyl-alpha-hydroxy acid compounds can inhibit weight growth of high-fat diet-induced obese model mice and reduce body fat. Compared with GLP-1 receptor weight loss drugs which achieve the effect of reducing weight by inhibiting appetite, the O-acyl-alpha-hydroxy acid compounds are not dependent on appetite inhibition, and can reduce side effects such as gastrointestinal discomfort and muscle loss caused by inhibiting appetite. When combined or sequentially administered with GLP-1 drugs, the O-acyl-alpha-hydroxy acid compounds can maintain or enhance the weight loss effect while improving the side effects caused by GLP-1, and can prevent the risk of significant weight rebound after stopping GLP-1 by maintaining body weight. The application provides a safe and effective new strategy for weight loss and lipid reduction.

The present invention relates to a use of Cyclo-His Pro (CHP) alone or zinc and Cyclo-His Pro (zinc and CHP, Cycloz) for inhibiting muscle loss or alleviating muscle function decline caused by anti-obesity drugs. More specifically, the present invention provides a pharmaceutical composition and a health functional food composition, which when administered in combination with an anti-obesity drug, exhibit an effect of inhibiting the anti-obesity drug-induced side effect of muscle loss while maintaining a weight loss effect, and exhibit an effect of preventing, alleviating, or treating sarcopenic obesity, and a method for inhibiting muscle loss or alleviating muscle function decline caused by an anti-obesity drug and a method for preventing, alleviating or treating sarcopenic obesity using same.

The present invention relates to novel use of a cathepsin L inhibitor Z-Phe-Tyr-CHO (C26H26N2O5), wherein the cathepsin L inhibitor Z-Phe-Tyr-CHO inhibits cancer progression and cachexia and muscle damage that are caused by cancer, and thus can be effectively used for preventing, ameliorating or treating cachexia and muscle loss, while having anticancer activity.

The invention discloses a leg rehabilitation training device, and particularly relates to the technical field of medical instruments.The leg rehabilitation training device comprises a supporting assembly, a fixing assembly is installed on the upper portion of the supporting assembly, a cavity is formed in the right portion of the fixing assembly, an adjusting assembly is installed in the cavity, and a driving assembly is installed in an inner cavity of the fixing assembly; a training assembly is installed in an inner cavity of the fixing assembly. According to the leg rehabilitation training device, a patient does not need to get out of the bed by himself or herself through the designed adjusting assembly, the patient can be gradually transited from a lying state to a standing state by adjusting the stable angle of the turnover bed, and the safety risks such as falling and collision caused by lower limb weakness and lack of balance feeling in the whole process are avoided; meanwhile, by simulating the standing state, leg muscles can naturally bear the body weight, core muscle groups such as quadriceps femoris muscles and gastrocnemius muscles can be activated, muscle loss atrophy caused by long-term bed lying can be prevented, bone metabolism can be stimulated through load bearing, and the occurrence risk of osteoporosis can be reduced.

The invention discloses lactobacillus delbrueckii with a muscle protection function in a fat reducing period as well as a product and application thereof, belongs to the technical field of microorganisms, and discloses lactobacillus delbrueckii subsp. Lactis Turb8 with the preservation number of CGMCC No.35627. The lactobacillus delbrueckii subsp. Lactis Turb8 has the advantages that the preservation number is CGMCC No.35627; the strain or the preparation thereof can effectively prevent or improve the accompanying problems of muscle loss and function decline in the process of applying fat-reducing drugs such as GLP-1 receptor agonists (such as liraglutide and semeglutide), and the effect of reducing fat but not reducing muscle is achieved. The strain disclosed by the invention can be used for remarkably increasing the lean body mass ratio of a user, increasing the muscle mass of lower limbs, increasing the cross sectional area of muscle fibers and improving muscle function indexes such as strength of four limbs and suspension endurance while keeping the original weight-reducing effect of a fat-reducing medicine. The invention also relates to microbial agents comprising this strain, various preparations, their use in the preparation of products for ameliorating (in particular drug-induced) muscle reduction.

The present application relates to a peptide exhibiting muscle loss prevention and muscle mass promotion activities, and use thereof, and provides: a peptide consisting of an amino acid sequence of SEQ ID NO: 1; a pharmaceutical composition for preventing or treating a muscle disease, comprising the peptide as an active ingredient; and a food composition for preventing or ameliorating a muscle disease, comprising the peptide as an active ingredient.

The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for improving senescence of a skeletal muscle system and application of the pharmaceutical composition. The pharmaceutical composition is composed of nicotinamide mononucleotide and apigenin. The composition has the advantages of being high in safety and easy to obtain, can synergistically promote cartilage, bone and muscle cell differentiation, delay cartilage degeneration and relieve bone and muscle loss, and has a good effect and application potential in the aspect of treating skeleton and muscle aging.

The present invention relates to a composition for strengthening muscle strength or preventing, ameliorating or treating muscle loss, comprising a Lilium lancifolium extract as an active ingredient. Specifically, when C2C12 cells were pre-treated with a Lilium lancifolium extract, and then treated with H2O2, dexamethasone, or TNF-α, muscle damage was alleviated and muscle loss was inhibited, and the muscle mass and grip strength decreased by dexamethasone administration in a muscle atrophy mouse model were increased upon administration of the Lilium lancifolium extract. Therefore, the composition can be effectively used as a health functional food, medicine or feed additive for strengthening muscle strength or preventing, ameliorating or treating muscle loss.

The present invention relates to a pharmaceutical composition for the prevention or treatment of sarcopenia in companion animals. The pharmaceutical composition inhibits an increase in the production and mRNA expression of myostatin protein, which directly affects muscle loss and reduced muscle strength, and thus can exhibit the effect of more fundamentally preventing or treating sarcopenia in companion animals.

The present invention provides a therapeutic drug for frailty or muscular dystrophy, and particularly for sarcopenia, and a medicinal drug for improving motor function. The present invention provides a motor function improver that contains a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof and additionally contains an ATP precursor substance or is used in combination with an ATP precursor substance. The ATP precursor substance is preferably inosine, inosinic acid, or hypoxanthine. This motor function improver is preferably used as a medicinal drug and is used as a therapy or preventive for frailty and sarcopenia and as a therapy or preventive for muscle wasting and muscle loss.

The invention discloses a traditional Chinese medicine composition for preventing and treating lower limb deep venous thrombosis and application thereof. The traditional Chinese medicine composition is prepared from rheum officinale, cassia twig, astragalus membranaceus, caulis spatholobi, corydalis tuber, radix paeoniae rubra, fructus kochiae and rhizoma atractylodis macrocephalae. According to the traditional Chinese medicine composition, static lower limb deep venous thrombosis caused by the same disease of ying and wei and concurrence of internal stagnation of blood stasis, vein injury and muscle loss is taken as a pathogenesis, medicines are reasonably combined, and rheum officinale is taken as a monarch medicine and is mainly used for cooling blood, removing blood stasis and stimulating menstrual flow; suberect spatholobus stem, corydalis tuber and red peony root are used as ministerial drugs for promoting blood circulation to remove meridian The cassia twig is used as an adjuvant drug to assist and prevent the rhubarb from being too cold; the radix astragali has the effects of tonifying qi and strengthening superficies, the rhizoma atractylodis macrocephalae has the effects of eliminating dampness and diminishing swelling, and the fructus kochiae has the effects of clearing heat, promoting diuresis, dispelling wind and arresting itching; all the medicines are reasonably combined to achieve the effects of regulating ying and wei so as to restore veins, and removing turbid and generating new energy so as to promote qi circulation, so that the effect of effectively relieving or curing the deep venous thrombosis of the lower limbs is achieved.

This invention discloses a *Lactococcus faecium* strain, YS-IM01. This strain can efficiently hydrolyze sheep colostrum proteins and specifically release a large amount of leucine. This invention also provides a polypeptide composition comprising multiple active peptides with potential for muscle synthesis, immunomodulation, and antioxidant activity. This invention further provides a fermented sheep colostrum product obtained by fermenting sheep colostrum with the aforementioned *Lactococcus faecium*. This invention also provides a method for preparing the fermented sheep colostrum product, comprising steps including fermentation, low-temperature vacuum concentration, and vacuum freeze-drying. Simultaneously, this invention also provides a method for preparing a drug using *Lactococcus faecium* and the polypeptide composition to prevent and / or improve age-related muscle loss.

The present invention provides a composition for preventing or treating muscular dystrophy, the composition comprising Zaltoprofen as an active ingredient. The composition according to the present invention increases the expression of utrophin, reduces the expression of myostatin, MAFbx, and MuRF1, and can inhibit muscle loss, increase muscle, and improve muscle function by inducing muscle differentiation and increasing the diameter of myotubes. Thus, the composition is expected to be used in various ways as medicines, quasi-medicines, fragrance materials, functional biomaterials, and functional food materials for alleviating, preventing, or treating muscular dystrophy.

Provided herein are compositions and methods for tissue repair. In particular, the compositions and methods described herein find use in repairing, regenerating, and modulating fibrosis and inflammation in a variety of tissues such as, for example, large volume muscle loss, including skeletal and heart muscle, blast wave injury, muscle loss from diabetes and resulting from frailty as a result of aging.

Provided is a pharmaceutical composition for preventing and treating muscle loss, containing Rhododendron mucronulatum extract as an active ingredient.

The invention relates to the technical field of active peptides, and particularly discloses an albumin anti-inflammatory peptide for improving muscle loss as well as a preparation method and application of the albumin anti-inflammatory peptide. The albumin anti-inflammatory peptide for improving muscle loss provided by the invention is prepared by mixing an NKVVR active peptide and an FDVFK active peptide, the amino acid sequence of the NKVVR active peptide is as follows: asparagine, lysine, valine, valine and arginine; the amino acid sequence of the FDVFK active peptide is as follows: phenylalanine, aspartic acid, valine, phenylalanine and lysine. The albumin anti-inflammatory peptide prepared by the invention can reduce individual inflammatory immune response, has good anti-inflammatory property, and can be applied to food for improving muscle loss or medicine for improving muscle loss.

The present disclosure relates to an albumin nanocomposite comprising a phytochemical and a composition for muscle disease comprising the same, and more specifically, to an albumin nanocomposite comprising a phytochemical that exhibits an effect of inhibiting muscle loss caused by oxidative stress or inflammatory response and promoting the differentiation of myoblasts into muscle cells. The albumin nanocomposite comprising the phytochemical effectively delivers the phytochemical by targeting immune cells that induce reactive oxygen species and inflammatory responses. Accordingly, by regulating muscle-loss signaling pathways induced by reactive oxygen species and inflammatory responses, the nanocomposite inhibits muscle cell atrophy and promotes differentiation. Therefore, a composition comprising the albumin nanocomposite comprising the phytochemical according to the present disclosure can be provided as a composition for improving, preventing, or treating muscle diseases.

Methods of treating muscle atrophy (e.g., reduced muscle mass or muscle loss) using GSK-3β inhibitors are provided.

The present invention relates to a peptide having obesity and muscle loss inhibitory activities, and a use thereof. The peptide has excellent effects on suppressing appetite, promoting energy metabolism, inhibiting fat accumulation, and promoting lipolysis, and inhibits muscle atrophy while promoting muscle synthesis, such that the peptide can be effectively used for the prevention or treatment of obesity and sarcopenia.

The application discloses ecdysterone-low molecular weight fructan composite microspheres with fat-reducing and muscle-increasing functions, and a preparation method and application thereof, and belongs to the technical field of biological medicine and functional food. The composite microspheres have a core-shell structure, the inner core is a calcium alginate gel, the outer shell is chitosan, the inner core co-encapsulates ecdysterone and low molecular weight fructan, and the mass ratio of the two is 0.8-1.2:1. The preparation adopts a liquid drop microfluidic technology combined with an internal gelation method to form the inner core, and adopts a post-crosslinking method to coat the outer shell. The composite microspheres are regular in shape, uniform in particle size, high in encapsulation rate, good in stability, excellent in pH response slow-release and anti-degradation characteristics in the gastrointestinal tract. In-vivo pharmacological experiments prove that the composite microspheres can reduce the body weight and body fat rate of obese mice, increase the lean meat content and muscle strength, realize synergistic effects of fat reduction and muscle increase, and can be used for preparing drugs or functional food for improving obesity-related muscle loss, low-muscle obesity and related metabolic syndrome.

The present invention relates to a peptide having muscle formation-promoting activity, anti-obesity activity, fatty liver-inhibiting activity, or anti-diabetic activity, and to a use thereof. Specifically, the peptide of the present invention exhibits activities of inhibiting muscle loss, increasing muscle mass, promoting lipid degradation in hepatocytes or adipocytes, suppressing insulin resistance signaling, or enhancing insulin sensitivity signaling. The peptide of the present invention can be effectively used as an active ingredient in a pharmaceutical composition or a food composition for treating, preventing, or alleviating muscle diseases, obesity, fatty liver, or diabetes.

The present invention relates to a use of a precursor miRNA for preventing, alleviating, or treating muscle loss or muscle atrophy and, more specifically, to a composition for preventing, alleviating, or treating diseases caused by muscle loss or muscle atrophy, the composition comprising the precursor miRNA or an expression regulator thereof. The precursor miRNA according to the present invention was experimentally confirmed to exhibit a specific expression pattern in individuals with muscle loss or muscle atrophy compared to a normal control group. This indicates that the precursor miRNA according to the present invention and the expression regulator thereof have the effect of preventing, alleviating, or treating muscle loss or muscle atrophy, and thus the precursor miRNA according to the present invention can be widely used in the field of treating muscle loss or muscle atrophy.